We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00159614
First Posted: September 12, 2005
Last Update Posted: January 29, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by:
NovaCardia, Inc.
September 7, 2005
September 12, 2005
January 29, 2008
September 2005
Not Provided
Comparison of KW-3902IV alone or with loop diuretic on renal function.
Same as current
Complete list of historical versions of study NCT00159614 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With Congestive Heart Failure (CHF) and Renal Impairment
The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
  • Heart Failure, Congestive
  • Renal Insufficiency
Drug: KW-3902IV
Not Provided
Dittrich HC, Gupta DK, Hack TC, Dowling T, Callahan J, Thomson S. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail. 2007 Oct;13(8):609-17.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
Not Provided
Not Provided

Inclusion Criteria:

  • Stable congestive heart failure
  • Impaired renal function
  • Taking oral loop diuretic

Exclusion Criteria:

  • Acutely decompensated (unstable) and end stage heart failure
  • Diuretics other than loop diuretics
  • Pregnant or nursing
  • Inability to follow instructions
  • Participation in another clinical trial within past 30 days
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00159614
CKI-203
Not Provided
Not Provided
Not Provided
Not Provided
NovaCardia, Inc.
Merck Sharp & Dohme Corp.
Not Provided
NovaCardia, Inc.
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP